Sansure Biotech Inc. (SHA:688289)

China flag China · Delayed Price · Currency is CNY
20.17
+0.32 (1.61%)
At close: Jan 23, 2026
0.60%
Market Cap11.58B
Revenue (ttm)1.67B
Net Income (ttm)271.49M
Shares Out574.18M
EPS (ttm)0.40
PE Ratio50.05
Forward PE34.58
Dividend0.54 (2.66%)
Ex-Dividend DateSep 23, 2025
Volume6,038,122
Average Volume5,671,304
Open19.91
Previous Close19.85
Day's Range19.87 - 20.20
52-Week Range17.73 - 26.36
Beta0.78
RSI57.37
Earnings DateApr 30, 2026

About Sansure Biotech

Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers nucleic acid and multiple nucleic acid diagnostic kits for coronavirus, CoV-2, influenza virus, and respiratory syncytial virus; DNA fluorescence and nucleic acid diagnostic kits for respiratory tract infections, HPV infections, and reproductive tract infections; nucleic acid tests and fluorescence diagnostic kits for blood-borne infections; RNA diagnostic kits for gastrointestinal infections; an... [Read more]

Sector Healthcare
Founded 2008
Employees 2,346
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688289
Full Company Profile

Financial Performance

In 2024, Sansure Biotech's revenue was 1.46 billion, an increase of 44.78% compared to the previous year's 1.01 billion. Earnings were 275.60 million, a decrease of -24.23%.

Financial Statements